Ken Griffin
ELVN icon

Ken Griffin’s Enliven Therapeutics ELVN Stock Holding History

Ken Griffin’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Buy
+36,100
New +$1M ﹤0.01% 6851
2025
Q2 		– Sell
-200
Closed -$3.94K – 13160
2025
Q1 		$3.94K Sell
200
-900
-82% -$19.4K ﹤0.01% 13928
2024
Q4 		$24.8K Buy
1,100
+1,000
+1,000% +$25.9K ﹤0.01% 13036
2024
Q3 		$2.55K Sell
100
-3,500
-97% -$81.1K ﹤0.01% 13738
2024
Q2 		$84.1K Buy
+3,600
New +$75.8K ﹤0.01% 11153
2023
Q4 		– Sell
-175
Closed -$2.39K – 14496
2023
Q3 		$2.39K Hold
175
– – ﹤0.01% 13728
2023
Q2 		$3.57K Sell
175
-2,350
-93% -$47.5K ﹤0.01% 13681
2023
Q1 		$55.3K Sell
2,525
-4,900
-66% -$99.7K ﹤0.01% 12028
2022
Q4 		$121K Sell
7,425
-250
-3% -$4K ﹤0.01% 10940
2022
Q3 		$70K Buy
+7,675
New +$45.3K ﹤0.01% 11384

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Ken Griffin's ELVN Position: Q1 2026 in Review

Ken Griffin increased its Enliven Therapeutics (ELVN) stake by 22% in Q1 2026, buying an estimated $8.85M and bringing the position to 1,743,915 shares worth $68.4M. The position accounts for 0.01% of the portfolio, ranked #1100.

Ken Griffin first reported a position in ELVN in Q1 2020 and has held it in 16 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Ken Griffin held 1,743,915 shares of Enliven Therapeutics worth $68.4M as of Q1 2026.
  • Ken Griffin bought 319,571 Enliven Therapeutics shares in Q1 2026, an estimated $8.85M.
  • Enliven Therapeutics made up 0.01% of Ken Griffin's portfolio in Q1 2026, its #1100 holding.
  • Ken Griffin first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.